P&G
27.3.2020 15:16:05 CET | Business Wire | Press release
Today the Procter & Gamble Company (NYSE:PG) announced donations totalling $10 million USD in personal health and hygiene, household products, sanitizers and financial support to help people in need, including families, elderly citizens and health professionals, enabling access to everyday essentials. As part of this effort, P&G is donating $1 million to support the International Federation of Red Cross and Red Crescent Societies’ (IFRC) COVID-19 appeal, as well as individual European Red Cross Red Crescent national societies’ efforts, to improve the lives of Europe’s vulnerable people across the continent during these challenging times.
Since the onset of the outbreak, P&G has been working with long-standing partner organizations to understand how to best support communities, relief agencies and those impacted by this global emergency. Today, we are taking three immediate actions to support urgent public needs.
Supporting vital health care services: We will donate an initial one million dollars to the IFRC and Red Cross Red Crescent National Societies to provide health care, medical supplies and hygiene education to vulnerable people across Europe.
IFRC Regional Director for Europe (ad interim), Elkhan Rahimov, said the donation would enable Red Cross and Red Crescent volunteers and staff across Europe to continue their vital and lifesaving work on the frontline of the COVID19 response.
“In these times of great emergency, this support will enable us to keep helping the most vulnerable in our society. Older people and immune compromised, those in quarantine and isolation, migrants and the homeless. We are truly appreciative of Procter and Gamble’s support,” Mr Rahimov said.
Improving lives at home with everyday essentials: Everyone at P&G is working diligently to maintain the production, distribution and availability of all our brands, not only for consumers but also for the comfort and confidence of the medical workers, emergency services and first responders who are on the frontline of the battle against COVID-19. We are also working with Red Cross and Red Crescent National Societies and local foodbanks, to deliver everyday cleaning, health and hygiene essentials to those who need it most. During these unprecedented times, our brands enable people to do the simple things – brush their teeth, wash their hair, shave, wear a clean shirt, change a baby diaper, keep homes and clothes clean – actions that can help restore a sense of normalcy and improve everyday life and wellbeing.
Providing hand and surface sanitizers: We are shifting manufacturing to help protect frontline workers. We recently started producing sanitizer in several P&G manufacturing sites in Europe, to ensure our people can continue operating safely and supporting hospitals, health authorities and relief organizations. We are building capacity to provide a minimum of 10,000 litres of hand sanitizer in 16 countries around Europe, enabling more than 3 million hand washes per week.
Loic Tassel, P&G President, Europe said, “In 30 years of working in the consumer goods industry, I have never experienced such challenging times impacting far more than businesses, but our neighbours, our communities – every facet of our lives. The P&G team is committed to doing everything possible to ensure the health and safety of all our employees, to continue to serve our consumers with essential products and services and to take meaningful action to help communities in need and those on the frontlines. Together, P&G and its organization partners are stepping up as a force for good in service to our communities.”.
We cannot predict how and when this crisis will end but we’re committed to be part of the solution. We have mobilized the full capabilities of P&G and our partners to help out in this time of need, and we will be there for our employees, consumers and communities — stepping up to be a force for good – however long it takes.
– ENDS –
Notes to the Editor
Visit https://www.pg.com/covid19 to learn how we’re stepping up to serve during the COVID-19 crisis.
About International Federation of Red Cross and Red Crescent Societies
About IFRC
IFRC is the world’s largest humanitarian network, comprising 192 National Red Cross and Red Crescent Societies working to save lives and promote dignity around the world.
www.ifrc.org - Facebook - Twitter - YouTube
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always® , Ambi Pur® , Ariel® , Bounty® , Charmin® , Crest® , Dawn® , Downy® , Fairy® , Febreze® , Gain® , Gillette® , Head & Shoulders® , Lenor® , Olay® , Oral-B® , Pampers® , Pantene® , SK-II® , Tide® , Vicks® , and Whisper® . The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com/ for the latest news and information about P&G and its brands.
To learn more, follow us on Twitter , LinkedIn , Instagram and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200327005286/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 14:05:00 CEST | Press release
Significant unmet need remains for 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burdenEnpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standardsELOWEN is a global Phase 3 program evaluating enpatoran’s impact on both skin and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 14:00:00 CEST | Press release
Celebrating the ecommerce leaders from Michael Kors and Gymshark shaping the future of fraud prevention and risk management Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are:Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 14:00:00 CEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
